ASCMICROPLAT
Fast Automated Multiplex Analysis of Neonatal Sepsis Markers on a Centrifugal Microfluidic Platform
| Coordinatore | HAHN-SCHICKARD-GESELLSCHAFT FUER ANGEWANDTE FORSCHUNG E.v.
Organization address
address: WILHELM-SCHICKARD-STRASSE 10 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 2˙574˙757 € |
| EC contributo | 1˙961˙627 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-01-01 - 2014-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
HAHN-SCHICKARD-GESELLSCHAFT FUER ANGEWANDTE FORSCHUNG E.v.
Organization address
address: WILHELM-SCHICKARD-STRASSE 10 contact info |
DE (Villingen) | coordinator | 668˙254.00 |
| 2 |
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Organization address
address: College Green - contact info |
IE (DUBLIN) | participant | 488˙315.00 |
| 3 |
MOBIDIAG OY
Organization address
address: KEILARANTA 16A contact info |
FI (ESPOO) | participant | 485˙083.00 |
| 4 |
ROHRER AG WERKZEUG- & MASCHINENBAU
Organization address
address: BREMENSTALLSTRASSE 1 contact info |
CH (MOHLIN) | participant | 244˙975.00 |
| 5 |
CHIMERA BIOTEC GMBH
Organization address
address: EMIL-FIGGE-STRASSE 76A contact info |
DE (DORTMUND) | participant | 75˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The global frequency of neonatal sepsis is 1-21 newborns per 1000 live births with mortality rates as high as 35-70%, amounting to 100,000s of annual cases. The consortium has identified a real and pressing need for increasing diagnostic efficacy in a setting that imposes a dramatic healthcare burden on EU (and global) healthcare management systems. The goal of this project is the realization and clinical validation of a fully integrated and automated platform for the parallel detection of neonatal sepsis markers and a panel of sepsis-causing bacteria from a clinical sample (whole blood, cerebrospinal fluid, fluid from joint aspirations or urine). For the first time, this will allow a fast (90 minutes) automated routine diagnosis of neonatal sepsis, permitting a timely and especially specific treatment.
The project has the potential to significantly reduce neonatal mortality and ensure appropriate treatment for one of the most vulnerable patient cohorts in the medical setting: newborns. The interaction between presence of microbial pathogens and the host (patient) response will be investigated in a clinical validation phase with a view to planning patient management more appropriately. In the long term this will also reduce the spread of multiresistant strains emerging from the unspecific use of broad-spectrum antibiotics.
ASCMicroPlat will cover the complete value chain from research and development to clinical validation. The system will be based on the centrifugal microfluidic platform of HSG-IMIT and an inventive foil-technology for the disposable test carriers, which is scalable to industrial production. ASCMicroPlat will enable a sepsis diagnosis based on a “sample in – result out” process. Additionally, the know-how generated in this project will provide innovative European SMEs with a platform for the fast implementation of lab-on-a-chip tests. The consortium has a strong industrial component including 2 SMEs.'